Company news
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news
Every Arrowhead Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 4
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
January 9, 2023
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
December 21, 2022
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
December 21, 2022
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
December 20, 2022
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 8, 2022
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 8, 2022
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
November 28, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
November 21, 2022
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
November 14, 2022
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
November 9, 2022
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
November 7, 2022
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
October 11, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
September 1, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
August 17, 2022
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
August 4, 2022
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
July 20, 2022
Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
July 5, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
June 7, 2022
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
May 26, 2022
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
May 10, 2022
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
May 9, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
May 2, 2022
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
May 2, 2022
Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
April 27, 2022
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
April 26, 2022
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
April 25, 2022
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
April 20, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
April 1, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
March 24, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
March 15, 2022
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
February 24, 2022
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
February 18, 2022
Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
February 17, 2022
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
February 2, 2022
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
January 24, 2022
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
January 21, 2022
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
January 12, 2022
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
December 20, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
November 30, 2021
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
November 22, 2021
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
November 22, 2021
Arrowhead Announces JNJ-75220795 in Development for NASH
November 17, 2021
Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
November 15, 2021
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
November 15, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
November 12, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
November 12, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
November 1, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
November 1, 2021
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
October 25, 2021
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
October 12, 2021